Literature DB >> 7866426

Characterization of cyclic nucleotide phosphodiesterase isoenzymes in the human ureter and their functional role in vitro.

A Taher1, P Schulz-Knappe, M Meyer, M Truss, W G Forssmann, C G Stief, U Jonas.   

Abstract

An increase in cyclic nucleotide monophosphate levels is suggested to play a prominent role in mediating smooth-muscle relaxation. Cyclic nucleotide phosphodiesterase (PDE) influences smooth-muscle tone by decreasing the level of cyclic nucleotides. At present, five different families of isoenzymes of PDE exist that show a distinct species- and organ-specific distribution. Our study was done to evaluate the existence of specific PDE isoenzymes and its functional role in human ureteral tissue. Normal ureteral tissue was homogenized and centrifuged and the supernatant fraction was separated using anioin-exchange diethylaminoethyl (DEAE)-Sephacel chromatography. A PDE assay was then performed and the peak fractions were added to different specific PDE activators and inhibitors. In vitro, longitudinal ureteral strips were precontracted and different selective and non-selective PDE inhibitors were added incremently. Three different PDE isoenzymes were characterized: PDE I (calmodulin-sensitive), PDE II (cGMP-stimulated), and PDE IV (cAMP-specific). All PDE inhibitors relaxed the strips dose-dependently, with the 50% effective concentrations (EC50) being 30 microM for papaverine, 40 microM for zaprinast, 25 microM for quazinone, and 0.1 microM for rolipram. The ureter-relaxing effect of the PDE IV inhibitor at low concentrations, combined with its low-level effect on the systemic circulatory parameters, may open the possibility of using selective PDE IV-inhibitors in the treatment of ureteral colics or for ureteral stone passage.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7866426     DOI: 10.1007/bf00191209

Source DB:  PubMed          Journal:  World J Urol        ISSN: 0724-4983            Impact factor:   4.226


  7 in total

Review 1.  Pharmacomechanical coupling in vascular smooth muscle cells--an overview.

Authors:  T Itoh
Journal:  Jpn J Pharmacol       Date:  1991-01

2.  Treatment of renal colic by prostaglandin synthetase inhibitors and avafortan (analgesic antispasmodic).

Authors:  A E el-Sherif; R Foda; L J Norlen; H Yahia
Journal:  Br J Urol       Date:  1990-12

Review 3.  Primary sequence of cyclic nucleotide phosphodiesterase isozymes and the design of selective inhibitors.

Authors:  J A Beavo; D H Reifsnyder
Journal:  Trends Pharmacol Sci       Date:  1990-04       Impact factor: 14.819

4.  Nonsteroidal anti-inflammatory drugs facilitate stone passage.

Authors:  M R Friedman
Journal:  Urology       Date:  1990-04       Impact factor: 2.649

5.  Multiple cyclic nucleotide phosphodiesterase activities from rat brain.

Authors:  W J Thompson; M M Appleman
Journal:  Biochemistry       Date:  1971-01-19       Impact factor: 3.162

6.  Resistance of a separated form of canine ureteral phosphodiesterase activity to inhibition by xanthines and papaverine.

Authors:  R M Weiss; J G Hardman; J N Wells
Journal:  Biochem Pharmacol       Date:  1981-08-15       Impact factor: 5.858

7.  Insulin activation of cyclic AMP phosphodiesterase in intact ureteral segments.

Authors:  R M Weiss; M A Wheeler
Journal:  J Pharmacol Exp Ther       Date:  1988-11       Impact factor: 4.030

  7 in total
  15 in total

Review 1.  Distribution and functional significance of phosphodiesterase isoenzymes in the human lower urinary tract.

Authors:  Stefan Uckert; Christian G Stief; Margit Mayer; Udo Jonas; Petter Hedlund
Journal:  World J Urol       Date:  2005-12-06       Impact factor: 4.226

2.  Adjunctive therapy to promote stone passage.

Authors:  Geoffrey R Nuss; Judson D Rackley; Dean G Assimos
Journal:  Rev Urol       Date:  2005

3.  In vitro effects of PDE5 inhibitors sildenafil, vardenafil and tadalafil on isolated human ureteral smooth muscle: a basic research approach.

Authors:  Christian Gratzke; Stefan Uckert; Giorgi Kedia; Oliver Reich; Boris Schlenker; Michael Seitz; Armin J Becker; Christian G Stief
Journal:  Urol Res       Date:  2006-11-11

4.  Does this case hold the answer to one of the worse types of pain in medicine--that of loin pain haematuria syndrome (LPHS).

Authors:  Alan Russell; Suman Chatterjee; Michael Seed
Journal:  BMJ Case Rep       Date:  2015-04-26

5.  Heterogeneity of neuronal and smooth muscle receptors involved in the VIP- and PACAP-induced relaxations of the pig intravesical ureter.

Authors:  Medardo Hernández; María Victoria Barahona; Paz Recio; Luis Rivera; Sara Benedito; Ana Cristina Martínez; Albino García-Sacristán; Luis M Orensanz; Dolores Prieto
Journal:  Br J Pharmacol       Date:  2003-12-08       Impact factor: 8.739

6.  The effect of diclofenac sodium and papaverine on isolated human ureteric smooth muscle.

Authors:  Abdullah Sivrikaya; Omer Fatih Celik; Nursel Sivrikaya; Guner Kemal Ozgur
Journal:  Int Urol Nephrol       Date:  2003       Impact factor: 2.370

7.  Cyclic nucleotide phosphodiesterase (PDE) isoenzymes in the human detrusor smooth muscle. I. Identification and characterization.

Authors:  M C Truss; S Uckert; C G Stief; M Kuczyk; U Jonas
Journal:  Urol Res       Date:  1996

8.  [PDE5 inhibitors. A new option in the treatment of ureteral colic?].

Authors:  C Gratzke; S Uckert; O Reich; B Schlenker; D Tilki; M Seitz; C G Stief
Journal:  Urologe A       Date:  2007-09       Impact factor: 0.639

9.  Safety and efficacy of silodosin and tadalafil in ease of negotiation of large ureteroscope in the management of ureteral stone: A prosective randomized trial.

Authors:  Rohit Bhattar; Vipin Jain; Vinay Tomar; Sher Singh Yadav
Journal:  Turk J Urol       Date:  2017-12-01

10.  Comparative efficacy of tamsulosin versus tamsulosin with tadalafil in combination with prednisolone for the medical expulsive therapy of lower ureteric stones: a randomized trial.

Authors:  Santosh Kumar; Kumar Jayant; Swati Agrawal; Shrawan Kumar Singh
Journal:  Korean J Urol       Date:  2014-03-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.